Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medical Developments International's revenue per share for the
six
months ended in Jun. 2026 was A$0.17.
Medical Developments International's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.36.
Warning Sign:
Medical Developments International Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Medical Developments International was 1.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -1.10% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 1.70% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 4.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Medical Developments International's Revenue per Share or its related term are showing as below:
ASX:MVP'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.4 Med: 6.9 Max: 25.3
Current: -1.1
During the past 13 years, Medical Developments International's highest 3-Year average Revenue Per Share Growth Rate was 25.30% per year. The lowest was -6.40% per year. And the median was 6.90% per year.
ASX:MVP's 3-Year Revenue Growth Rate is ranked worse than 63.43% of 905
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs ASX:MVP: -1.10
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Medical Developments International Revenue per Share Related Terms
Medical Developments International Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International Revenue per Share Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medical Developments International's PS Ratio falls into.
Medical Developments International Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.36
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (ASX:MVP) has a Revenue per Share of A$0.36 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Medical Developments International and its competitors. According to the industry distribution chart, Medical Developments International ranks #574 out of 905 companies in the Drug Manufacturers industry, placing it in the top 63.4%.
Is Medical Developments International's Revenue per Share too high?
Medical Developments International's current Revenue per Share is A$0.36. Based on the distribution chart, Medical Developments International ranks #574 out of 905 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medical Developments International has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's Revenue per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #574 out of 905 companies for Revenue per Share. This places Medical Developments International in the lower half of its industry. The industry median Revenue per Share is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.70, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current Revenue per Share is A$0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.53, compared to a current price of A$0.50 — trading 5.7% below its estimated fair value. The current Revenue per Share is A$0.36. Medical Developments International's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current Revenue per Share is A$0.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.50 is trading 5.7% below its estimated GF Value™ of A$0.53.
GuruFocus considers Medical Developments International to be Fairly Valued.
Key valuation signals for ASX:MVP:
Revenue per Share: A$0.36
GF Value™: A$0.53 vs. price of A$0.50 (5.7% below fair value)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
55GF Score
Get the complete analysis for ASX:MVP
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
